



Health and Wellbeing Board
6 December 2018

PNA supplementary statement

Purpose of the report:

To ask the Health and Wellbeing Board (HWB) to approve the Pharmaceutical Needs Assessment (PNA) supplementary statement (Annexe One) for publishing following approval of a pharmacy merger by NHS England

Recommendations:

1. It is recommended that the HWB approves the supplementary statement (Annexe One) that must be issued in response to the approval of the pharmacy consolidation in Merstham (as detailed in Annexe One) by NHS England, and agrees to its publication on the basis that there will not be a gap in pharmaceutical service provision created as a result of the merger.

Introduction:

2. Amendments to the NHS (Pharmaceutical Services and Local Pharmaceutical Services) Regulations 2013 relating to pharmacy consolidation applications require that:
 - 2.1 After approval of a pharmacy consolidation by NHS England (for which the HWB has already made representations – Annexe Two), the HWB must issue a supplementary statement to the effect that it agrees the removal of the pharmacy premises from the pharmaceutical list does not create a gap in pharmaceutical services provision,
 - 2.2 Any such statement becomes part of the HWB pharmaceutical needs assessment once published.

Conclusions:

3. The pharmacy consolidation in question has been approved by NHS England. The HWB has already made representations to the effect that a gap in pharmaceutical service provision will not be created so a supplementary statement to that effect must now be issued.

Next steps:

4. Following approval by the HWB the supplementary statement will be published alongside the 2018 PNA on Surrey-i at which point it becomes part of the PNA.

Report contact: Julie George, Public Health Consultant

Contact details: Julie.george@surreycc.gov.uk

Sources/background papers:

Annex One: Supplementary statement for publication;

Annex Two: HWB letter to NHS England summarising representations regarding the merger.